| MLK3 (MAP3K12) | |
|---|---|
| Gene | [MAP3K12](/genes/map3k12) |
| UniProt | Q9UHC3 |
| PDB | 2J7O, 2R0B |
| Mol. Weight | ~103 kDa |
| Localization | Cytoplasm, Membrane, Neuronal dendrites |
| Family | MAP3K (Mitogen-Activated Protein Kinase Kinase Kinase) family |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntingtons-disease), [Stroke](/diseases/stroke) |
MLK3 (Mixed-Lineage Kinase 3), also known as MAP3K12, is a serine/threonine protein kinase that functions as a key regulator of the MAPK signaling pathways. It plays critical roles in neuronal development, stress responses, and cell death pathways. MLK3 has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and stroke, where it contributes to both protective and detrimental cellular responses[1].
MLK3 (MAP3K12) is a member of the MAP3K family that activates the JNK and p38 MAPK pathways. It contains multiple functional domains including a kinase domain, a leucine zipper for dimerization, a CRIB (Cdc42/Rac interactive binding) domain, and a C-terminal regulatory region. MLK3 is expressed in various tissues, with high expression in the brain where it participates in neuronal signaling, synaptic plasticity, and stress responses[2].
MLK3 is a multi-domain serine/threonine protein kinase:
MLK3 activation involves:
MLK3 is a primary activator of stress-activated protein kinases:
In neurons, MLK3:
MLK3 can promote neuronal apoptosis:
MLK3 also has neuroprotective functions:
MLK3 contributes to AD pathogenesis:
In PD, MLK3:
In HD, MLK3:
In cerebral ischemia, MLK3:
MLK3 is a potential therapeutic target:
Gallo KA, Mark MR, Scadden DT, et al. Identification and characterization of a novel member of the mixed lineage kinase family. 1994. ↩︎
Rana A, Gallo KA. The mixed lineage kinase 3 (MLK3) signaling cascade: implications for development and disease. 2006. ↩︎
Leung IW, Lassam N. The activation loop and phosphorylation of PAK a dictate the stability and function of MLK3. 2001. ↩︎
Yang J, New L, Jiang Y, et al. Molecular cloning and characterization of a human protein kinase that specifically activates the JNK pathway. 1998. ↩︎
Kloss B, Ranganathan R. Mixed lineage kinase activity is required for axonal morphogenesis. 2004. ↩︎
Zhang Y, Yao Y, Qiu X, et al. MLK3 in neurodegeneration: friend or foe? Mol Neurobiol. 2019. ↩︎